



Eli Lilly and Company

Lilly Corporate Center
Indianapolis, Indiana 46285
(317) 276-2000

November 7, 1991

Mr. Bernard M. Kosloski
Director, Life Sciences Group
Research Corporation Technologies, Inc.
6840 East Broadway Boulevard
Tucson, Arizona 85710-6400

Re: License Agreement Nos. 1873 and 1874

Dear Bernie:

I regret to report that we have encountered sever toxicity with Hal Kohn's anticonvulsant, LY274959. Accordingly, we have decided to discontinue development of the compound, and to terminate our license agreement. Please find enclosed termination notices for both agreements, No. 1873 and 1874. I will be happy to send you a full toxicity report once it is available if you wish.

Very truly yours,

Charles W. Ashbrook
Assistant General Patent Counsel

CWA:jc

Enclosures